SCIENTIFIC PUBLICATIONS
Recent Publications
- Implications of subclinical tuberculosis for vaccine trial design and global effect. Churchyard GJ, Houben RMGJ, Fielding K, Fiore-Gartland AL, Esmail H, Grant AD, Rangaka MX, Behr M, Garcia-Basteiro AL, Wong EB, Hatherill M, Mave V, Dagnew AF, Schmidt AC, Hanekom WA, Cobelens F, White RG. Lancet Microbe. 2024 Jul 1. doi: 10.1016/S2666-5247(24)00127-7. Epub ahead of print.
- The BCG vaccine, advantages, and disadvantages of introducing new generation vaccines against Mycobacterium tuberculosis. Ari MM, Beig M, Sholeh M, Khoshmirsafa M. Clin Exp Vaccine Res. 2024 Jul;13(3):184-201. doi: 10.7774/cevr.2024.13.3.184. Epub 2024 Jul 31.
- Immune responses induced by Mycobacterium tuberculosis heat-resistant antigen (Mtb-HAg) upon co-administration with Bacillus Calmette-Guérin in mice. Guo F, Wei J, Song Y, Song J, Wang Y, Li K, Li B, Qian Z, Wang X, Wang H, Xu T. Cytokine. 2024 Jul;179:156610. doi: 10.1016/j.cyto.2024.156610. Epub 2024 Apr 18.
- Bergenin potentiates BCG efficacy by enriching mycobacteria-specific adaptive memory responses via the Akt-Foxo-Stat4 axis. Mukhopadhyay S, Pahuja I, Okieh AA, Pandey D, Yadav V, Bhaskar A, Dwivedi VP. Bergenin potentiates BCG efficacy by enriching mycobacteria-specific adaptive memory responses via the Akt-Foxo-Stat4 axis. Tuberculosis (Edinb). 2024 Jul;147:102517. doi: 10.1016/j.tube.2024.102517. Epub 2024 May 8.
- Recent efforts in the development of glycoconjugate vaccine and available treatment for tuberculosis. Banoo S, Yadav Y, Tyagi R, Manna A, Sagar R. Recent efforts in the development of glycoconjugate vaccine and available treatment for tuberculosis. Bioorg Chem. 2024 Jul 1;150:107610. doi: 10.1016/j.bioorg.2024.107610. Epub ahead of print.
- Ag85B with c-di-AMP as mucosal adjuvant showed immunotherapeutic effects on persistent Mycobacterium tuberculosis infection in mice. Liang X, Cui R, Li X, Ning H, Kang J, Lu Y, Zhou S, Huang X, Peng Y, Zhang J, Li S, Ma Y, Bai Y. Braz J Med Biol Res. 2024 Jul 1;57:e13409. doi: 10.1590/1414-431X2024e13409.
- Splenic marginal zone B cells restrict Mycobacterium tuberculosis infection by shaping the cytokine pattern and cell-mediated immunity. Tsai CY, Oo M, Peh JH, Yeo BCM, Aptekmann A, Lee B, Liu JJJ, Tsao WS, Dick T, Fink K, Gengenbacher M. Splenic marginal zone B cells restrict Mycobacterium tuberculosis infection by shaping the cytokine pattern and cell-mediated immunity. Cell Rep. 2024 Jul 2;43(7):114426. doi: 10.1016/j.celrep.2024.114426. Epub ahead of print.
- Single-cell sequencing: Current applications in various tuberculosis specimen types. Zeng Y, Ma Q, Chen J, Kong X, Chen Z, Liu H, Liu L, Qian Y, Wang X, Lu S. Single-cell sequencing: Current applications in various tuberculosis specimen types. Cell Prolif. 2024 Jul 2:e13698. doi: 10.1111/cpr.13698. Epub ahead of print.
- A modified mycobacterial growth inhibition assay for the functional assessment of vaccine-mediated immunity. Vergara EJ, Tran AC, Paul MJ, Harrison T, Cooper A, Reljic R. A modified mycobacterial growth inhibition assay for the functional assessment of vaccine-mediated immunity. NPJ Vaccines. 2024 Jul 2;9(1):123. doi: 10.1038/s41541-024-00906-z.
- The whole genome sequence of Polish vaccine strain Mycobacterium bovis BCG Moreau. Krysztopa-Grzybowska K, Lach J, Polak M, Strapagiel D, Dziadek J, Olszewski M, Zasada AA, Darlińska A, Lutyńska A, Augustynowicz-Kopeć E. The whole genome sequence of Polish vaccine strain Mycobacterium bovis BCG Moreau. Microbiol Spectr. 2024 Jul 2;12(7):e0425923. doi: 10.1128/spectrum.04259-23. Epub 2024 May 17.
- Chimeric antigen carried by extracellular vesicles induces stronger protective immunity against Mycobacterium tuberculosis infection. Ji L, Fu Y, Xiong S. Chimeric antigen carried by extracellular vesicles induces stronger protective immunity against Mycobacterium tuberculosis infection. Immunobiology. 2024 Jul 2;229(5):152834. doi: 10.1016/j.imbio.2024.152834. Epub ahead of print.
- Enhanced efficacy of BCG vaccine formulated in adjuvant is dependent on IL-17A expression. Derrick SC, Yang A, Cowley S. Enhanced efficacy of BCG vaccine formulated in adjuvant is dependent on IL-17A expression. Tuberculosis (Edinb). 2024 Jul 6;148:102540. doi: 10.1016/j.tube.2024.102540. Epub ahead of print.
- Immunogenicity and vaccine potential of clinical isolate Mycobacterium kansasii strain against Mycobacterium tuberculosis infection. Kim H, Shin SJ. Microbiol Spectr. 2024 Jul 9. doi: 10.1128/spectrum.00819-24. Epub ahead of print.
- Immunoinformatics and structural aided approach to develop multi-epitope based subunit vaccine against Mycobacterium tuberculosis. Sci Rep. 2024 Jul 10. doi: 10.1038/s41598-024-66858-5.
- Humanized Mouse Models of Bacterial Infections. McDonald K, Rodriguez A, Muthukrishnan G. Antibiotics (Basel). 2024 Jul 11;13(7):640. doi: 10.3390/antibiotics13070640.
- Specific CD4+ T cell phenotypes associate with bacterial control in people who ‘resist’ infection with Mycobacterium tuberculosis. Sun M, Phan JM, Kieswetter NS, Huang H, Yu KKQ, Smith MT, Liu YE, Wang C, Gupta S, Obermoser G, Maecker HT, Krishnan A, Suresh S, Gupta N, Rieck M, Acs P, Ghanizada M, Chiou SH, Khatri P, Boom WH, Hawn TR, Stein CM, Mayanja-Kizza H, Davis MM, Seshadri C. Specific CD4+ T cell phenotypes associate with bacterial control in people who ‘resist’ infection with Mycobacterium tuberculosis. Nat Immunol. 2024 Jul 12. doi: 10.1038/s41590-024-01897-8. Epub ahead of print.
- Novel structure of secreted small molecular weight antigen Mtb12 from Mycobacterium tuberculosis. Han JH, Kim DY, Lee SY, Park HH. Biochem Biophys Res Commun. 2024 Jul 12;717:150040. doi: 10.1016/j.bbrc.2024.150040. Epub 2024 May 4.
- Boosting Immunogenicity of a Recombinant Mycobacterium smegmatis Strain via Zinc-Dependent Ribosomal Proteins. Singh S, Kanzin D, Chavez S, Saavedra-Avila NA, Ng TW, Lukose R, Mayer O, Kim J, Chen B, Chen M, Porcelli SA, Jacobs WR Jr, Tiwari S. Boosting Immunogenicity of a Recombinant Mycobacterium smegmatis Strain via Zinc-Dependent Ribosomal Proteins. Biomedicines. 2024 Jul 15;12(7):1571. doi: 10.3390/biomedicines12071571.
- Lung-resident CD3-NK1.1+CD69+CD103+ Cells Play an Important Role in Bacillus Calmette-Guérin Vaccine-Induced Protective Immunity against Mycobacterium tuberculosis Infection. Durojaye O, Vankayalapati A, Paidipally P, Mukherjee T, Vankayalapati R, Radhakrishnan RK. Lung-resident CD3-NK1.1+CD69+CD103+ Cells Play an Important Role in Bacillus Calmette-Guérin Vaccine-Induced Protective Immunity against Mycobacterium tuberculosis Infection. J Immunol. 2024 Jul 15:ji2200728. doi: 10.4049/jimmunol.2200728. Epub ahead of print.
- Immunogenic profiling of Mycobacterium tuberculosis Rv1513 reveals its ability to switch on Th1 based immunity. Shi Z, Zhou L, Wang X, Zhang Z, Kong L, Zhang Y. Immunogenic profiling of Mycobacterium tuberculosis Rv1513 reveals its ability to switch on Th1 based immunity. Arch Microbiol. 2024 Jul 16;206(8):352. doi: 10.1007/s00203-024-04033-0.
- Unveiling the Significance of LysE in Survival and Virulence of Mycobacterium tuberculosis: A Review Reveals It as a Potential Drug Target, Diagnostic Marker, and a Vaccine Candidate. Upadhyay S, Dhok A, Kashikar S, Quazi ZS, Agarkar VB. Vaccines (Basel). 2024 Jul 16;12(7):779. doi: 10.3390/vaccines12070779.
- Adjuvant system AS01: from mode of action to effective vaccines. Roman F, Burny W, Ceregido A, Laupèze B, Temmerman ST, Warter L, Coccia M. Adjuvant system AS01: from mode of action to effective vaccines. Expert Rev Vaccines. 2024 Jul 23. doi: 10.1080/14760584.2024.2382725. Epub ahead of print.
- From pathogenesis to antigens: the key to shaping the future of TB vaccines. Yang H, Lei X, Chai S, Su G, Du L. Front Immunol. 2024 Jul 23;15:1440935. doi: 10.3389/fimmu.2024.1440935.
- Estimating the Potential Public Health Value of BCG Revaccination. Clark RA, Sumner T, Weerasuriya CK, Bakker R, Scriba TJ, White RG. Estimating the Potential Public Health Value of BCG Revaccination. J Infect Dis. 2024 Jul 25;230(1):e139-e143. doi: 10.1093/infdis/jiae089.
- Novel prophylactic and therapeutic multi-epitope vaccine based on Ag85A, Ag85B, ESAT-6, and CFP-10 of Mycobacterium tuberculosis using an immunoinformatics approach. Nugraha MF, Changestu DA, Ramadhan R, Salsabila T, Nurizati A, Pratiwi SE, Ysrafil Y. Osong Public Health Res Perspect. 2024 Jul 26. doi: 10.24171/j.phrp.2024.0026. Epub ahead of print.
- A multistage protein subunit vaccine as BCG-booster confers protection against Mycobacterium tuberculosis infection in murine models. Chen Z, Zhang Y, Wu J, Xu J, Hu Z, Fan XY. A multistage protein subunit vaccine as BCG-booster confers protection against Mycobacterium tuberculosis infection in murine models. Int Immunopharmacol. 2024 Jul 27;139:112811. doi: 10.1016/j.intimp.2024.112811. Epub ahead of print.
- A mucosal vaccine formulation against tuberculosis by exploiting the adjuvant activity of S100A4-A damage-associated molecular pattern molecule. Abil OZ, Liu S, Yeh YW, Wu Y, Sen Chaudhuri A, Li NS, Deng C, Xiang Z. A mucosal vaccine formulation against tuberculosis by exploiting the adjuvant activity of S100A4-A damage-associated molecular pattern molecule. Vaccine. 2024 Jul 31:126151. doi: 10.1016/j.vaccine.2024.07.052. Epub ahead of print.
Contact us with recent publications (within last 30 days) sharing new data, approaches, and information on TB vaccine R&D